Dataset Information

Incidence of Diabetes After Cancer Development: A Korean National Cohort Study.

ABSTRACT:

Importance

Diabetes is an established risk factor for developing cancer. A limited body of evidence also suggests that cancer can increase the risk of developing new cases of diabetes, but the evidence is inconclusive.

Objective

To evaluate whether the development of cancer is associated with increasing risk of subsequent diabetes.

Design, setting, and participants

This cohort study included a nationally representative sample of the Korean general population observed for up to 10 years (January 1, 2003, to December 31, 2013). A total of 524?089 men and women 20 to 70 years of age without diabetes and with no history of cancer at baseline were included.

Exposures

Incident cancer (time-varying exposure).

Main outcomes and measures

Incident type 2 diabetes using insurance claim codes.

Results

During 3?492?935.6 person-years of follow-up (median follow-up, 7.0 years) in 494?189 individuals (50.0% female; mean [SD] age, 41.8 [12.5] years), 15?130 participants developed cancer and 26?610 participants developed diabetes. After adjustment for age, sex, precancer diabetes risk factors, metabolic factors, and comorbidities, the hazard ratio (HR) for diabetes associated with cancer development was 1.35 (95% CI, 1.26-1.45; P?Conclusions and relevanceIn this large Korean cohort, cancer development increased the risk of subsequent diabetes. These data provide evidence that cancer is associated with an increased risk of diabetes in cancer survivors independent of traditional diabetes risk factors. Physicians should remember that patients with cancer develop other clinical problems, such as diabetes, with higher frequency than individuals without cancer, and should consider routine diabetes screening in these patients.

SUBMITTER: Hwangbo Y

PROVIDER: S-EPMC6143049 | biostudies-literature | 2018 Aug

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Incidence of Diabetes After Cancer Development: A Korean National Cohort Study.

Hwangbo Yul Y Kang Danbee D Kang Minwoong M Kim Saemina S Lee Eun Kyung EK Kim Young Ae YA Chang Yoon Jung YJ Choi Kui Son KS Jung So-Youn SY Woo Sang Myung SM Ahn Jin Seok JS Sim Sung Hoon SH Hong Yun Soo YS Pastor-Barriuso Roberto R Guallar Eliseo E Lee Eun Sook ES Kong Sun-Young SY Cho Juhee J

JAMA oncology 20180801 8

<h4>Importance</h4>Diabetes is an established risk factor for developing cancer. A limited body of evidence also suggests that cancer can increase the risk of developing new cases of diabetes, but the evidence is inconclusive.<h4>Objective</h4>To evaluate whether the development of cancer is associated with increasing risk of subsequent diabetes.<h4>Design, setting, and participants</h4>This cohort study included a nationally representative sample of the Korean general population observed for up ...[more]

PMID: 29879271

Similar Datasets

Project description:Repeated weight fluctuation has been proposed as a potential risk factor for increasing morbidity and mortality including cancer. We aimed to investigate the association between body weight variability (BWV) and all cancer and site-specific cancer incidence and the impact of smoking on these associations. A total of 1,759,848 cancer-free male subjects who had their weight measured at least 5 times from the National Health Insurance Service-Health Screening Cohort from 2002 to 2011 were included and followed up until 2015. BWV was defined as the average absolute difference between successive values (ASV). The risk of cancer and site-specific cancer from BWV was identified using Cox proportional hazards regression analysis using hazard ratios (HRs) and 95% confidence intervals (CIs) adjusted for potential confounders including weight, and stratified analysis was also conducted according to smoking status. During the 7,015,413 person-years of follow-up, 11,494 patients (0.65%) developed new-onset cancers. BWV was associated with a higher risk of all cancers after adjustment for confounders. The highest BWV quintile group compared to the lowest had greater risks of all cancers and site-specific cancers including lung, liver, and prostate cancer (HR 1.22, 95% CI 1.15-1.30; HR 1.22, 95% CI 1.07-1.39; HR 1.46, 95% CI 1.19-1.81; HR 1.36, 95% CI 1.15-1.62, in all cancers, lung, liver and prostate cancer, respectively). Due to small number of cancer occurrence, the risk of kidney cancer was increased, but statistically insignificant (HR 1.38, 95% CI 0.91-2.10). Similar results were observed in noncurrent smokers. However, in current smokers, the risks of all cancers and only prostate cancer were significantly increased in the highest BWV quintile group (HR 1.19, 95% CI 1.09-1.31; HR 1.51, 95% CI 1.08-2.11). The risk of kidney cancer also increased in this group, although the finding was not statistically significant (HR 1.77, 95% CI 0.87-3.63) This study suggested BWV is an independent risk factor for cancer in men, especially in lung, liver, and prostate cancer, but evidence was weaker in kidney cancer. This association remained significant only in prostate cancer in current smokers.

Project description:The epidemiological literature suggests that insulin resistance, hyperinsulinemia, and increased levels of insulin-like growth factors place patients with type 2 diabetes mellitus (T2DM) at greater risk of cancer. The association between cancer incidence and the use of antidiabetic medications in patients with T2DM has been recently examined. There have been conflicting reports regarding an association between metformin and cancer risk. The aim of this study was to investigate the relationship between metformin use and the incidence of cancer in Koreans with T2DM.Data from The Korean National Diabetes Program (KNDP, 2006-2014), a nationwide, large-scale, prospective, multicenter cohort study in Korea, were used to study patients with T2DM. Patients ?30 years old whose complete medical records were available were included in this study. Patients with a history of any cancer on KNDP registration or those who had been diagnosed with any type of cancer within 1 year of metformin use were excluded. Survival curves with respect to the incidence of cancer were plotted using the Kaplan-Meier method. Hazard ratios and 95% confidence intervals for cancer were estimated in a Cox proportional hazards regression analysis.During a mean 5.8 years of follow-up, 164 of the 1918 study patients (335 metformin nonusers and 1583 metformin users) developed cancer. The incidence per 1000 person-years was 21.8 in metformin nonusers and 13.2 in metformin users. Metformin users had a reduced risk of cancer, even after adjustment for demographic characteristics, metabolic parameters, diabetic complications, and other antidiabetic medications (hazard ratio 0.513, 95% confidence interval 0.318-0.826, P?=?.0060). Subgroup analysis of metformin users showed a reduced risk of cancer in males, patients?<?65 years of age, patients with a T2DM duration?<?5 years, nonobese patients, nonsmokers, and good glycemic control group.This large-scale, prospective, multicenter cohort study demonstrated an association between metformin use and reduced cancer risk in patients with T2DM.

Dataset Information

Incidence of Diabetes After Cancer Development: A Korean National Cohort Study.

Importance

Objective

Design, setting, and participants

Exposures

Main outcomes and measures

Results

Publications

Incidence of Diabetes After Cancer Development: A Korean National Cohort Study.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure